醫(yī)療特長(zhǎng)：
從事醫(yī)教研工作30多年，具有豐富的臨床經(jīng)驗(yàn),，致力肝臟疾病的診治,，尤其擅長(zhǎng)脂肪性肝病、病毒性肝病,、自身免疫性肝病,、藥物性肝病等。
榮獲首屆嶺南名醫(yī),、羊城好醫(yī)生稱號(hào),。負(fù)責(zé)成立中山一院脂肪肝診治中心,，組建脂肪肝多學(xué)科診療團(tuán)隊(duì)，率先開展國(guó)際前沿的診療方法,。參與多個(gè)中國(guó)臨床指南的制定,，包括：2022年肝硬化合并糖尿病患者血糖管理專家共識(shí)、2019年脂肪性肝病診療規(guī)范化的專家建議,、2018年非酒精性脂肪性肝病防治指南,、2018年酒精性肝病防治指南等。
研究方向：
1,、脂肪性肝病
2,、病毒性肝病（乙肝,、丙肝等）
3,、自身免疫性肝病
4、藥物性肝病
主要教育和工作經(jīng)歷：
1984年醫(yī)學(xué)本科畢業(yè)后相繼獲碩士及博士學(xué)位,，曾在著名學(xué)府美國(guó)斯坦福大學(xué) (Stanford University）醫(yī)學(xué)院消化內(nèi)科完成博士后研究,。
社會(huì)兼職：
1、中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)脂肪肝和酒精肝學(xué)組委員
2,、中華醫(yī)學(xué)會(huì)消化病學(xué)分會(huì)肝膽組委員
3,、中華醫(yī)學(xué)會(huì)老年醫(yī)學(xué)分會(huì)消化病學(xué)組委員
4、廣東省醫(yī)學(xué)會(huì)肝臟病學(xué)分會(huì)副主任委員兼脂肪肝學(xué)組組長(zhǎng)
5,、廣東省肝病學(xué)會(huì)脂肪肝專業(yè)委員會(huì)主任委員
6,、廣東省臨床醫(yī)學(xué)學(xué)會(huì)脂肪肝專委會(huì)主任委員
7、廣東省健康管理學(xué)會(huì)脂肪肝多學(xué)科診治專業(yè)委員會(huì)主任委員
8,、廣東省醫(yī)學(xué)會(huì)感染病學(xué)分會(huì)常委
9,、廣東省醫(yī)師協(xié)會(huì)感染病學(xué)分會(huì)常委
10、廣東省預(yù)防醫(yī)學(xué)會(huì)感染病學(xué)專業(yè)委員會(huì)常委
論著：發(fā)表研究論文多篇,，2022年和2009年在著名雜志Metabolism (IF: 13.9) 和Hepatology (IF: 17.3 ) 發(fā)表論著,。近5年代表作如下：
- Feng X, Lin Y, Zhuo S, Zhi D, Shao C, Ye J, Zhong B（通訊作者）. Treatment of Obesity and Metabolic-Associated Fatty Liver Disease with a Diet or Orlistat: A Randomized Controlled Trial. Am J Clin Nutr 2023; S0002-9165(23)04154-0. (IF: 8.472)
- Shao C, Xu L, Lei P, Wang W, Feng S, Ye J, Zhong B（通訊作者）. Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease. J Transl Med 2023; 21: 12. (IF: 8.440)
- Shao C, Ye J, Li X, Lin Y, Feng S, Liao B, Wang W, Gong X, Zhong B（通訊作者）. Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment. J Clin Transl Hepatol 2022; 10: 1013-1026. (IF: 5.065)
- Lin Y, Feng X, Cao X, Miao R, Sun Y, Li R, Ye J, Zhong B（通訊作者）. Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. Diabetol Metab Syndr 2022; 14: 181. (IF: 5.395)
- Ye J, Zhuang X, Li X, Gong X, Sun Y, Wang W, Feng S, Wu T, Zhong B（通訊作者）. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation. Metabolism 2022; 136: 155294. (IF: 13.934)
- He J, Ye J, Sun Y, Feng S, Chen Y, Zhong B（通訊作者）. The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease. Nutrients 2022;14: 3587. (IF: 6.706)
- Luo L, Ye J, Shao C, Lin Y, Sun Y, Feng S, Wang W, Zhong B（通訊作者）. Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection. Nutrients 2022;14:2114. (IF: 6.706)
- Wu T, Ye J, Gong X, Li X, Shao C, Li F, Lin Y, Ma Q, Mai W, Wang W, Feng ST, Zhong B（通訊作者）. Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. Dig Liver Dis 2021; 53: 1610-1619. (IF: 5.165)
- Wu T, Ye J, Shao C, Li F, Lin Y, Ma Q, Wang W, Feng S, Zhong B（通訊作者）. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:691556. (IF: 6.055)
- Shi Y, He F, Chen J, Deng H, Shi J, Zhao C, Mi Y, Zou Z, Zhou Y, Di F, Zheng R, Du Q, Shang J, Yang R, Popovic B, Zhong B（通訊作者）, Fan J. Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 2021; 9: 607-614. (IF: 5.065)
- Li F, Ye J, Sun Y, Lin Y, Wu T, Shao C, Ma Q, Liao X, Feng S, Zhong B（通訊作者）. Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients. Diabetes Metab J 2021; 45: 417-429. (IF: 5.893)
- Lin Y, Gong X, Li X, Shao C, Wu T, Li M, Li F, Ma Q, Ye J, Zhong B（通訊作者）. Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China. Front Med (Lausanne) 2021; 7: 584396. (IF: 5.058)
- Ye J, Wang W, Feng S, Huang Y, Liao X, Kuang M, Xie X, Liao B, Zhong B（通訊作者）. Precise fibrosis staging with shear wave elastography in chronic hepatitis B depends on liver inflammation and steatosis. Hepatol Int 2020; 14: 190-201. (IF: 9.029)
- Ye J, Wu Y, Li M, Gong X, Zhong B（通訊作者）. Keratin 8 Mutations Were Associated With Susceptibility to Chronic Hepatitis B and Related Progression. J Infect Dis 2020; 221: 464-473. (IF: 7.759)
- Shao C, Ye J, Li F, Feng S, Wang W, Zhong B（通訊作者）. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Dig Liver Dis 2019; 51: 1392-1399. (IF: 5.165)
- Ye J, Hu X, Wu T, Wu Y, Shao C, Li F, Lin Y, Feng S, Wang W, Zhong B（通訊作者）. Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study. Diabetol Metab Syndr 2019; 11: 45. (IF: 5.395)
科研基金：
主持國(guó)家級(jí)、省部級(jí)和廣州市重大專項(xiàng)研究項(xiàng)目多項(xiàng)
主編或參編專著：
1,、脂肪肝看名醫(yī)(中山大學(xué)出版社)
2,、脂肪肝中西醫(yī)診治（中華醫(yī)學(xué)會(huì)繼續(xù)教育教材）
3,、中華老年醫(yī)學(xué)（人民衛(wèi)生出版社）
4,、老年醫(yī)學(xué)專科培訓(xùn)教材
5,、老年醫(yī)學(xué)住院醫(yī)師規(guī)范化培訓(xùn)教材
其他主要工作成績(jī)（比如獲獎(jiǎng)情況）：
多次接受包括羊城晚報(bào),、廣州日?qǐng)?bào)、新快報(bào),、39健康網(wǎng),、騰訊網(wǎng),、廣東電臺(tái)南方生活直播等多家主流媒體采訪。
